Galera Therapeutics, Inc.
galeratx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 14, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2026.
10-Q for Q1 FY2026, filed May 14, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops a drug that blocks nitric oxide synthase for patients with aggressive breast cancers, including metaplastic and treatment-resistant triple-negative breast cancer.
10-K for FY2025, filed Mar 19, 2026On December 30, 2024, we completed the acquisition of Nova Pharmaceuticals, Inc. (Nova), a privately-held biotechnology company advancing a…View ↗
Following the sale to Biossil, our portfolio is now comprised of a pan-NOS inhibitor. Our lead program is a Phase 1/2 trial of the pan-NOS…View ↗
Metaplastic breast cancer (MpBC) is a particularly aggressive form of TNBC that has no satisfactory or approved treatment today and is the…View ↗
How Did They Make Money?
No revenue was reported.
10-K for FY2025, filed Mar 19, 2026
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 14, 2026
−$1.6MView ↗
- ▲ +1% (Loss)
- vs −$1.6M in Q1 FY2025
-
Aug 4, 2026
Galera completed its merger with Obsidian
Galera became a wholly owned subsidiary of Parent, which changed its name to Obsidian Therapeutics; Galera common stock converted into Parent common stock.
Sources
8-K, filed Aug 4, 2026
Effective at 8:30 a.m. eastern time on August 3, 2026, the parties to the Merger Agreement consummated the Mergers, and effective at 4:39…View ↗
From radiation drugs to breast cancer
The earlier report centered on dismutase-mimetic drugs intended to reduce radiotherapy side effects and improve its cancer effects; the latest report centers on a drug that blocks nitric oxide synthase for advanced breast cancer after selling the earlier assets.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 19, 2026We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics…View ↗
We are a biopharmaceutical company that historically was focused on developing a portfolio of small molecule superoxide dismutase (SOD)…View ↗
On December 30, 2024, we completed the acquisition of Nova Pharmaceuticals, Inc. (Nova), a privately-held biotechnology company advancing a…View ↗
Following the sale to Biossil, our portfolio is now comprised of a pan-NOS inhibitor. Our lead program is a Phase 1/2 trial of the pan-NOS…View ↗
Loading...
